Two testing options for determining eligibility for access to Pharmaceutical Benefits Schedule-subsidised aducanumab in patients with early stage Alzheimer disease
Record ID 32007000865
English
Details
Project Status:
Ongoing
URL for project:
http://msac.gov.au
URL for protocol:
http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1643-public
Anticipated Publish Date:
2022
URL for additional information:
http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1643-public
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
MeSH Terms
- Positron-Emission Tomography
- Alzheimer Disease
- Antibodies, Monoclonal, Humanized
- Amyloid beta-Peptides
Contact
Organisation Name:
Medical Services Advisory Committee
Contact Address:
MSAC (MDP 107), GPO Box 9848, Canberra, ACT 2601, Australia. Tel: +61 2 6289 6811; Fax: +61 2 6289 8799.
Contact Name:
msac.secretariat@health.gov.au
Contact Email:
msac.secretariat@health.gov.au
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.